Podcast

HBV Treatment Decision-Making

Launch Date
12/15/2020
Credit Amount
0.00 Expired
Credit Expires
12/15/2021

Faculty

Kris V. Kowdley, MD, FACP, FACG, AGAF, FAASLD
Moderator
Professor
Elson S. Floyd College of Medicine
Washington State University
Spokane, WA
Director, Liver Institute Northwest
Medical Director and Senior Scientific Advisor
Velocity Clinical Research
Seattle, WA
Paul Y. Kwo, MD
Professor of Medicine
Director of Hepatology, Stanford University School of Medicine, Stanford, CA
Paul Y. Kwo, MD
Professor of Medicine

Dr. Kwo is currently Professor of Medicine and Director of Hepatology at Stanford University where he joined the faculty in November 2016. Prior to joining the faculty at Stanford, he was at Indiana University for 21 years where he served as the Medical Director of Liver Transplantation. He received his MD from Wayne State University School of Medicine, his Internal Medicine training at University of Maryland, and his Gastroenterology/Hepatology training at Mayo Clinic Rochester. He is an Associate Editor for Clinical and Molecular Hepatology and serves on the editorial boards of multiple journals including Hepatology, Hepatology Communications, and Clinical and Molecular Hepatology. His service to the ACG has included membership of the Education Committee and International Relations Committee, and Chair of the Membership Committee.

In addition, Dr. Kwo is a co-director of the ACG Hepatology Circle, as well as the ACG Hepatology School and serves on the ACG Board of Trustees. Along with other ACG members, he recently authored the ACG Practice Guideline Evaluation of Abnormal Liver Chemistries. He has distinguished himself in the field of chronic Hepatitis C and has served as the principal investigator for multiple seminal trials in the treatment of hepatitis C that have been published in journals including the New England Journal of Medicine, Lancet, Gastroenterology, Hepatology, Journal of Hepatology and others. He has won multiple awards for his clinical care and teaching, and he believes in the importance of mentoring college students, medical students, residents, fellows and faculty in clinical research.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

Chronic hepatitis B virus (HBV) is a serious public health concern that is often underrated despite the approval of newer therapies and subsequent updated guidelines. Integrating guideline-directed treatment can reduce the morbidity and mortality associated with HBV.

In this second episode of the four-part CMEOCast Podcast to Practice series “Meeting Patients Where They Live: Community-Based Efforts to Improve Screening and Treatment of HBV,” faculty experts will discuss the efficacy and safety profiles of current agents for HBV, guiding clinicians through best practices when initiating or switching treatment. In addition, while there is currently no cure for HBV, considering the promise for the future, faculty experts will define “functional cure” for HBV and its application to agents in development.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Optimize efficacy and safety profiles of current agents when initiating or switching treatment in patients with HBV
  • Define functional cure for HBV and how it applies to HBV agents in development.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Summarize how to optimize efficacy and safety profiles of current agents when initiating or switching treatment for patients with HBV
  • Define functional cure for HBV and how it applies to HBV agents in development.

Financial Support

Supported by an educational grant from Gilead Sciences, Inc.

Target Audience

Primary care physicians, OB/GYNs, emergency department physicians, PAs, nurse practitioners, and pharmacists.

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.
Activity UAN: 0376-0000-20-168-H01-P

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit ™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Kowdley reports that he receives research support from Conatus Pharmaceuticals Inc.; CymaBay Therapeutics; Enanta Pharmaceuticals, Inc.; Genfit; Gilead Sciences, Inc.; GlaxoSmithKline; HighTide Therapeutics Inc.; Intercept Pharmaceuticals, Inc.; and Zydus Pharmaceuticals, Inc. He is on the advisory committee for Assembly Biosciences, Inc.; Blade Therapeutics; Boehringer Ingelheim; Merck & Co., Inc.; and Roche. He is on the speakers bureau for AbbVie Inc.; Gilead Sciences, Inc.; and Intercept Pharmaceuticals, Inc.

Dr. Kwo reports that he receives grants from Assembly Biosciences, Inc.; Bristol-Myers Squibb; and Gilead Sciences, Inc. He is on the advisory committee for Aligos Therapeutics, Inc. and Gilead Sciences, Inc. He receives other financial or material support as a Data and Safety Monitoring Board (DSMB) member for Janssen Pharmaceuticals, Inc.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

  • Kashemi Rorie, PhD (planning committee)
  • Susan Perry (planning committee)
  • Jan Perez (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

 

NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-168-H01-P.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

PD-036-121520-47

HBV Treatment Decision-Making
Event Date: 12/15/2020